The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer.
 
Emanuela Ferraro
No Relationships to Disclose
 
Enrico Moiso
No Relationships to Disclose
 
Anton Safonov
No Relationships to Disclose
 
Luc Cabel
No Relationships to Disclose
 
Laura Loudon
No Relationships to Disclose
 
Chau T. Dang
Consulting or Advisory Role - Daichii Sankyo; Gilead Sciences; Novartis; Pfizer; Race Oncology; ROCHE/Genentech; Seagen
Research Funding - Genentech/Roche (Inst)
Travel, Accommodations, Expenses - ROCHE/Genentech
 
Sherry Shen
Honoraria - MJH Life Sciences
Research Funding - Merck (Inst); Sermonix Pharmaceuticals (Inst)
 
Komal L. Jhaveri
Consulting or Advisory Role - Abbvie; AstraZeneca; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Sanofi; Scorpion Therapeutics; Seagen; Sun Pharma Advanced Research Company; Synthon; Taiho Oncology
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Clovis Oncology (Inst); Context Therapeutics (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Scorpion Therapeutics (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gilead Sciences; Intellisphere; Jounce Therapeutics; Lilly; Pfizer; Taiho Pharmaceutical
 
Mark E. Robson
Consulting or Advisory Role - Change HealthCare
Research Funding - Artios (Inst); AstraZeneca (Inst); Merck (Inst); Pfizer (Inst); Zenith Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - AstraZeneca; Clinical Care Options; Clinical Education Alliance; MJH Healthcare Holdings, LLC; MyMedEd; Pfizer; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Artios; GlaxoSmithKline; Merck; Pfizer; Tempus; Zenith Pharmaceuticals
 
Sarat Chandarlapaty
Stock and Other Ownership Interests - Odyssey Biosciences; Totus Medicines
Consulting or Advisory Role - AstraZeneca/MedImmune; Boxer Capital; Inivata; Lilly; Novartis; Paige.ai; Prelude Therapeutics; SAGA Diagnostics; Sanofi
Research Funding - Ambryx (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Paige.ai (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for (1) targeting mutant ER with ER PROTACS and (2) targeting CDK4/6 with CDK4/6 PROTACS (Inst)
Travel, Accommodations, Expenses - Novartis Institutes for BioMedical Research
Other Relationship - Peerview; Targeted Oncology; WebMD
(OPTIONAL) Uncompensated Relationships - Odyssey Biosciences; Totus Medicines
 
Pedram Razavi
Stock and Other Ownership Interests - Odyssey Biosciences
Honoraria - Daiichi Sankyo/Astra Zeneca; Pfizer
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Epic Sciences; Guardant Health; Loxo/Lilly; Myriad Genetics; NeoGenomics Laboratories; Novartis; PAIGE.AI; Prelude Therapeutics; SAGA Diagnostics; Tempus
Research Funding - AstraZeneca (Inst); Biovica (Inst); Epic Sciences (Inst); GRAIL (Inst); Guardant Health (Inst); Hologic/Biotheranostics (Inst); Illumina (Inst); Invitae (Inst); Myriad Genetics (Inst); NeoGenomics Laboratories (Inst); Novartis (Inst); Tempus (Inst)
 
Shanu Modi
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; DualityBio; Genentech; Gilead Sciences; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; DualityBio; Genentech; Gilead Sciences; GlaxoSmithKline; Lilly; Macrogenics; Puma Biotechnology; Seagen; Zymeworks
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); DualityBio (Inst); Nuvation Bio (Inst); Roche/Genentech (Inst); Seagen (Inst)